BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

<p>SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) &#8212; BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the JMP Securities [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/bioatla-to-participate-in-the-jmp-securities-hematology-and-oncology-summit/">BioAtla to Participate in the JMP Securities Hematology and Oncology Summit</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>